{"id":"rsvpref3-vaccine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site pain"},{"rate":"5-15%","effect":"Fever"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the administration of a vaccine that contains a weakened form of the RSV virus, which triggers the body's immune system to produce antibodies and immune cells that can recognize and fight the virus. The vaccine is designed to provide long-term protection against severe RSV disease.","oneSentence":"The RSVPreF3 vaccine works by stimulating the body to produce a protective immune response against the respiratory syncytial virus (RSV).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:02.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants and young children"}]},"trialDetails":[{"nctId":"NCT04732871","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-02-15","conditions":"Respiratory Syncytial Virus Infections","enrollment":1720},{"nctId":"NCT05705440","phase":"PHASE3","title":"A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-02-07","conditions":"Respiratory Syncytial Virus Infections","enrollment":3855},{"nctId":"NCT07220109","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":750},{"nctId":"NCT06534892","phase":"PHASE3","title":"An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-08-01","conditions":"Respiratory Syncytial Virus Infections","enrollment":10212},{"nctId":"NCT07092865","phase":"PHASE2","title":"A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-06","conditions":"Respiratory Syncytial Virus Infections","enrollment":184},{"nctId":"NCT06551181","phase":"PHASE3","title":"A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-08-05","conditions":"Respiratory Syncytial Virus Infections","enrollment":2621},{"nctId":"NCT06374394","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":841},{"nctId":"NCT06614725","phase":"PHASE3","title":"A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-10-01","conditions":"Respiratory Syncytial Virus Infections","enrollment":751},{"nctId":"NCT07050732","phase":"PHASE2","title":"Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-12-04","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":170},{"nctId":"NCT07203365","phase":"PHASE3","title":"RSV Immunogenicity Study in the Elderly (RISE)","status":"RECRUITING","sponsor":"Karin Karin Loré","startDate":"2025-08-25","conditions":"RSV Immunisation","enrollment":65},{"nctId":"NCT06389487","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":1459},{"nctId":"NCT05921903","phase":"PHASE2","title":"A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-28","conditions":"Respiratory Syncytial Virus Infections","enrollment":386},{"nctId":"NCT04886596","phase":"PHASE3","title":"Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-25","conditions":"Respiratory Syncytial Virus Infections","enrollment":26675},{"nctId":"NCT05879107","phase":"PHASE3","title":"Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-05-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1113},{"nctId":"NCT05966090","phase":"PHASE3","title":"A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-28","conditions":"Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections","enrollment":530},{"nctId":"NCT05590403","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-28","conditions":"Respiratory Syncytial Virus Infections","enrollment":1544},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT05559476","phase":"PHASE3","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-20","conditions":"Respiratory Syncytial Virus Infections","enrollment":1029},{"nctId":"NCT04841577","phase":"PHASE3","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-04-27","conditions":"Respiratory Syncytial Virus Infections","enrollment":976},{"nctId":"NCT04138056","phase":"PHASE2","title":"A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-11-05","conditions":"Respiratory Syncytial Virus Infections","enrollment":509},{"nctId":"NCT05045144","phase":"PHASE3","title":"A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1586},{"nctId":"NCT05059301","phase":"PHASE3","title":"A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-01","conditions":"Respiratory Syncytial Virus Infections","enrollment":770},{"nctId":"NCT04657198","phase":"PHASE2","title":"Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-12-09","conditions":"Respiratory Syncytial Virus Infections","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RSVPreF3 vaccine","genericName":"RSVPreF3 vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"The RSVPreF3 vaccine works by stimulating the body to produce a protective immune response against the respiratory syncytial virus (RSV). Used for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants and young children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}